As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't

A close­ly watched “break­through” asth­ma drug has hit all the right notes in a Phase III, As­traZeneca and Am­gen say, paving the way to reach a cur­rent­ly un­tapped pa­tient pop­u­la­tion.

We’re not get­ting much be­yond the an­nounce­ment that teze­pelum­ab met the pri­ma­ry end­point, but ex­ecs’ en­thu­si­as­tic com­ments sug­gest that what they’re see­ing backs up the “un­prece­dent­ed” re­sults that ce­ment­ed their FDA break­through des­ig­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER